-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $7

Benzinga·03/24/2025 12:07:01
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $11 to $7.